Consistently, HSCs administrated by alanine-serine-cysteine transporter type-2 (ASCT2), Mannan-binding lectin (MBL) and a PPARγ agonist (15d-PGJ2) resulted in liver fibrosis attenuation through senescence induction in HSCs [48,49,50]. Here, MBL2 is linked to Hepatic fibrosis.